Eli Lilly (LLY) ACCELERATE Trial Proves 'Modestly Positive' for Esperion Therapeutics (ESPR) LDL Hypothesis - Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Piper Jaffray Cuts Price Target on Eli Lilly & Co. (LLY) Following Announced Discontinuation of Evacetrapib
October 13, 2015 8:38 AM EDTPiper Jaffray reiterated an Overweight rating on Eli Lilly (NYSE: LLY), and cut the price target to $118.00 (from $120.00), following the company's announced discontinuation of its CETP inhibitor evacetrapib. LLY's stock fell by 7.8% following the announcement.
Analyst Richard Purkiss commented, "Yesterday, LLY's stock fell by 7.8%... More
Discontinuation of Evacetrapib Study Could Provide Modest Boost to Esperion's (ESPR) ETC-1002
October 12, 2015 1:01 PM EDTChardan Capital affirms Esperion Therapeutics (Nasdaq: ESPR) at Neutral with a price target of $18 after Eli Lilly & Co. announced that it and the ACCELERATE study's academic leadership have accepted the recommendation of the independent data monitoring committee to terminate the Phase 3 trial of the investigational medicine evacetrapib, due to insufficient efficacy. Lilly will discontinue... More
Lilly's (LLY) CETP Inhibitor Disappointment Seen as Positive for Esperion (EPSR) and PCSK-9, Says RBC (REGN) (AMGN) (SNY) (MDCO) (MRK)
October 12, 2015 9:13 AM EDTNews Eli Lilly (NYSE: LLY) plans to halt development of evacetrapib, a CETP inhibitor, has positive implications for PCSK-9 -related stocks and Esperion Therapeutics (NASDAQ: ESPR), said RBC analyst Michael J. Yee.
Yee explained, "The CETP class of drugs has been the primary competitive threat to other drugs like AMGN (Nasdaq: AMGN), REGN's (Nasdaq: REGN) PCSK-9 drugs now approved and ESPR's Phase III oral drug ETC-1002. Recall there is also one... More
UPDATE: Esperion (ESPR), Others Gains After Lilly Halts Development of Evacetrapib; Merch (MRK) Falls
October 12, 2015 8:15 AM EDT(Updated - October 12, 2015 8:30 AM EDT)
Esperion Therapeutics (NASDAQ: ESPR) gained pre-market Monday after Eli Lilly & Co. (NYSE: LLY) discontinued development of Evacetrapib. Other gainers include makers of PCSK9 cholesterol drugs Regeneron (NASDAQ:... More
